Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Squamous Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Squamous Cell Neoplasm

Cancer Family

Squamous Cell Neoplasm

CI-CAN-00000359Explore in graph →

Non-malignant1,024 active trials9 approved drugs78 evidence items

NCIt: C3792
MeSH: D018307

Overview
Statistics
Survival
Genomics26
Variants & evidence78
Drugs35
Trials3210
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (75)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 10, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 75 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
· Ann Otol Rhinol Laryngol · 2017 · PMID 28061634 · validated civic_curation pubmed
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
· Cancer Discov · 2014 · PMID 24302556 · validated civic_curation pubmed
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
· N Engl J Med · 2012 · PMID 22256804 · validated civic_curation pubmed
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
· Sci Transl Med · 2010 · PMID 21160078 · validated civic_curation pubmed
Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.
· Cancer Cell · 2011 · PMID 21840482 · validated civic_curation pubmed
Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
· Cancer Biol Ther · 2015 · PMID 26046389 · validated civic_curation pubmed
FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.
· Clin Cancer Res · 2015 · PMID 26015511

Showing 51–75 of 75 publications

← Previous
1
2
3
Next →

· validated civic_curation

Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.

· J Oral Pathol Med · 2016 · PMID 25677871 · validated civic_curation pubmed

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

· Clin Cancer Res · 2016 · PMID 26589432 · validated civic_curation pubmed

Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.

· Oncogene · 2016 · PMID 25982282 · validated civic_curation pubmed

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

· Proc Natl Acad Sci U S A · 2013 · PMID 24277854 · validated civic_curation pubmed

Li et al. Clin Cancer Res 2015

· 2015 · PMID 25589618 · validated cbioportal_study pubmed

Thind, Amarinder Singh et al. Front Oncol 2022

· 2022 · PMID 35982973 · validated cbioportal_study pubmed

Chang et al. NPJ Genom Med 2021

· 2021 · PMID 34272401 · validated cbioportal_study pubmed

Song et al. Nature 2014

· 2014 · PMID 24670651 · validated cbioportal_study pubmed

Lin et al. Nat Genet 2014

· 2014 · PMID 24686850 · validated cbioportal_study pubmed

Aidan et al. Nature 2025

· 2025 · PMID 40097403 · validated cbioportal_study pubmed

Stransky et al. Science 2011

· 2011 · PMID 21798893 · validated cbioportal_study pubmed

Agrawal et al. Science 2011

· 2011 · PMID 21798897 · validated cbioportal_study pubmed

Pickering et al. Cancer Discov 2013

· 2013 · PMID 23619168 · validated cbioportal_study pubmed

TCGA, Nature 2015

· 2015 · PMID 25631445 · validated cbioportal_study pubmed

Shankha Satpathy et al. 2021 Cell.

· 2021 · PMID 34358469 · validated cbioportal_study pubmed

· PMID 22960745 · validated cbioportal_study pubmed

Han et al. Exp Mol Med 2018

· 2018 · PMID 29422544 · validated cbioportal_study pubmed

Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

· JCI Insight · 2018 · PMID 29467336 · validated civic_curation pubmed